Standard Treatment Recommendations for Advanced Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)

被引：0
|
作者：
Smith, Abraham T. [1 ]
机构：
[1] Univ Penn, Perelman Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA
来源：
JOURNAL OF THE PANCREAS | 2022年 / 23卷 / 07期
关键词：
Pancreas; Pancreatitis; Pancreatic cell electrical activity; Insulin secretion;
D O I：
10.35841/1590-8577-23.7.757
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NETs), also known as carcinoids and islet cell tumours, are tumours produced from neuroendocrine cells that can arise anywhere along the gastrointestinal system. They are a diverse family of neoplasms with a broad and complex clinical range. Neuroendocrine tumours are tumours that arise in neuroendocrine cells, which are specialized cells. Neuroendocrine cells share characteristics with nerve cells and hormone-producing cells. Neuroendocrine tumours are uncommon and can develop anywhere in the body. Endocrinol cells found in the gastroenteric mucosa as well as those found in the pancreas, mostly comprising islets of Langerhans, are referred to as Gastroenteropancreatic (GEP) endocrine cells.
引用
收藏
页码：68 / 69
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of capecitabine and temozolomide (CAPTEM) in advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) - A systematic review and metanalysis
    Tacelli, M.
    Massironi, S.
    Gallo, C.
    Bina, N.
    Stornello, C.
    Arcidiacono, P. G.
    Capurso, G.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 238 - 238
  • [42] The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Saif, Wasif M.
    Parikh, Rohan
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh P.
    Soares, Heloisa
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Patterns of Treatment and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): Results from Multicenter Database of China
    Cheng, F.
    Wei, W.
    Zhiwei, Z.
    NEUROENDOCRINOLOGY, 2017, 105 : 66 - 66
  • [44] Genomic Profiling Distinguishes Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (GEP-NEC) from Small Cell Lung Carcinoma (SCLC)
    Bergsland, Emily
    Roy, Ritu
    Elvin, Julia
    Graeme-Cook, Fiona
    Bailey, Mark
    Stephens, Phil
    Ross, Jeffrey
    Olshen, Adam
    PANCREAS, 2017, 46 (03) : 427 - 427
  • [45] Neuroendocrine gastroenteropancreatic tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Oberg, K.
    Jellic, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 104 - 105
  • [46] The Sequencing of Lanreotide (LAN) After Octreotide LAR (OCT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Saif, Wasif M.
    Parikh, Rohan C.
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Halfdanarson, Thorvardur R.
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh
    Soares, Heloisa
    PANCREAS, 2019, 48 (03) : 450 - 450
  • [47] Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/ etoposide combined chemotherapy
    Wang, Yangdi
    Chen, Jie
    Song, Chenyu
    Shi, Siya
    Li, Ziping
    Feng, Shi-Ting
    Luo, Yanji
    EUROPEAN JOURNAL OF RADIOLOGY, 2022, 147
  • [48] Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
    J. Capdevila
    J. Hernando
    A. Teule
    C. Lopez
    R. Garcia-Carbonero
    M. Benavent
    A. Custodio
    A. Garcia-Alvarez
    A. Cubillo
    V. Alonso
    A. Carmona-Bayonas
    T. Alonso-Gordoa
    G. Crespo
    P. Jimenez-Fonseca
    M. Blanco
    A. Viudez
    A. La Casta
    I. Sevilla
    A. Segura
    M. Llanos
    S. Landolfi
    P. Nuciforo
    J. L. Manzano
    Nature Communications, 14
  • [49] Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
    Capdevila, J.
    Hernando, J.
    Teule, A.
    Lopez, C.
    Garcia-Carbonero, R.
    Benavent, M.
    Custodio, A.
    Garcia-Alvarez, A.
    Cubillo, A.
    Alonso, V.
    Carmona-Bayonas, A.
    Alonso-Gordoa, T.
    Crespo, G.
    Jimenez-Fonseca, P.
    Blanco, M.
    Viudez, A.
    La Casta, A.
    Sevilla, I.
    Segura, A.
    Llanos, M.
    Landolfi, S.
    Nuciforo, P.
    Manzano, J. L.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [50] Impact of nutritional status in the quality of life (QoL) of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain: NUTRIGETNE Study
    Del Olmo-Garcia, M.
    Garcia-Carbonero, R.
    Hernando, J.
    Perez-Wert, P.
    Suarez Gutierrez, L.
    Bellver, M.
    Alonso, V
    Serrano, R.
    Valdes, N.
    Melian, M.
    Febrero, B.
    Argente Pla, M.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 94 - 94
12345